Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.430
-0.010 (-0.69%)
At close: Dec 5, 2025, 4:00 PM EST
1.420
-0.010 (-0.70%)
After-hours: Dec 5, 2025, 6:22 PM EST
Allogene Therapeutics Revenue
In the year 2024, Allogene Therapeutics had annual revenue of $22.00K, down -76.84%.
Revenue (ttm)
$22.00K
Revenue Growth
-76.84%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
229
Market Cap
321.36M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ALLO News
- 26 days ago - Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T - Seeking Alpha
- 4 weeks ago - Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting - GlobeNewsWire
- 5 weeks ago - Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update - GlobeNewsWire
- 2 months ago - Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript - Seeking Alpha
- 3 months ago - Allogene Therapeutics Announces Participation in Upcoming Investor Conference - GlobeNewsWire